A LONGITUDINAL COMPREHENSIVE GERIATRIC ASSESSMENT TO DEFINE FITNESS IN FIRST-LINE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS AGED ≥65 YEARS: A PROSPECTIVE MULTICENTER ITALIAN STUDY (CLYF TRIAL) (SIE 2026) - Oct 6, 2026 - Abstract #C040; Pres time: Sep 21, 2026; 03:40 PM - 05:10 PM; Location: HALL 4; "Secondary: feasibility, impact of baseline characteristics on PGA domains; distribution of PGA/EORTC QLQ-C30 global health status (GHS) across treatments, lon- gitudinal changes.167 pts were included (Mar 2025–Jan 2026): 58% BTKi, 33.5% ibrutinib-venetoclax, 8.4% veneto- clax-obinutuzumab. Even among "fit" by traditional criteria, PGA identified frailer pts not con- sidered suitable for fixed-duration. These findings support in- tegrating dynamic PGA and QoL assessment into CLL man- agement."
Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Movement Disorders • TP53
|
|
A. M. Frustaci1; A. Zappaterra1; A. Galitzia2; E. Lovato3; C. Vitale4; M. Nicolosi5; C. Borella6; V. Bolis7; G. Quaresmini8; M. Gentile9; S. Marinoni10; L. Appio11; A. Giordano12; A. Visentin13; G. Farina14; V. Rossi15; F. Bagnoli16; E. Boccellato17; E. Lista18; A. Molteni19; G. Turri20; V. Del Fabro21; M. Deodato1; F. Perutelli4; A. Noto1; M. Varettoni22; M. Motta3; R. Murru2; A. Ferrario23; A. Tedeschi1
|